# How Lipfendra, Inclisiran, and New Guidelines Are Changing Cholesterol Management
New cholesterol medications and updated clinical guidelines are expanding treatment options for families dealing with high cholesterol. Two medications in particular—Lipfendra and Inclisiran—represent meaningful advances for patients who haven't responded well to traditional statins.
Lipfendra combines bempedoic acid with lesinurad, targeting cholesterol reduction through a different mechanism than statins. The drug works by blocking xanthine oxidase, an enzyme involved in uric acid and cholesterol production. Inclisiran takes a different approach altogether, using RNA interference technology to reduce PCSK9 protein production. This allows the liver to absorb more LDL cholesterol from the bloodstream. Inclisiran requires injections just twice yearly after an initial loading period, making it convenient for patients managing chronic conditions.
These options matter most for families with familial hypercholesterolemia or those whose cholesterol remains dangerously high despite maximum statin doses. Children and adults with genetic predisposition to high cholesterol now have pathways beyond pills alone.
Updated clinical guidelines reflect this expanding toolkit. Cardiologists and primary care doctors increasingly use these medications not as last resorts but as part of stepped treatment plans. Doctors now consider individual risk factors, family history, and treatment tolerance when choosing approaches rather than defaulting to one-size-fits-all statin therapy.
The practical takeaway for families involves conversations with their doctors about whether newer options suit their situations. Not every elevated cholesterol case requires these medications. Statins remain first-line treatment for most people. However, families managing aggressive cholesterol despite lifestyle changes or medication side effects should ask specifically about Lipfendra and Inclisiran eligibility.
Cost remains a consideration, as these newer medications typically carry higher price tags than